tiprankstipranks
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
PremiumPress ReleasesAtossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
26d ago
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
PremiumPress Releases
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
28d ago
Atossa Therapeutics presents data from 40mg cohort of Phase 2 EVANGELINE trial
PremiumThe Fly
Atossa Therapeutics presents data from 40mg cohort of Phase 2 EVANGELINE trial
28d ago
Atossa Therapeutics provides five-year (Z)-endoxifen update
PremiumThe FlyAtossa Therapeutics provides five-year (Z)-endoxifen update
2M ago
Atossa Therapeutics provides five-year Z-Endoxifen treatment update
PremiumThe Fly
Atossa Therapeutics provides five-year Z-Endoxifen treatment update
2M ago
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved “Expanded Access” Program for a U.S. Breast Cancer Patient
PremiumPress Releases
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved “Expanded Access” Program for a U.S. Breast Cancer Patient
2M ago
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
PremiumPress ReleasesAtossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
2M ago
Atossa Therapeutics announces first patient dosing of Z-endoxifen
PremiumThe Fly
Atossa Therapeutics announces first patient dosing of Z-endoxifen
3M ago
Atossa Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Atossa Therapeutics initiated with a Buy at H.C. Wainwright
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100